共 50 条
- [41] Utility of pre- and post-pembrolizumab (Pembro) Vesical Imaging-Reporting and Data System (VIRADS) to predict the pathological response in muscle-invasive urothelial bladder cancer (MIBC): An analysis of the PURE-01 cohort.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41Brembilla, GiorgioBasile, GiuseppeBandini, MarcoRaggi, DanieleMarandino, Laurade Padua, Tiago CostaPatane, Damiano AlfioCrupi, EmanueleDel Prete, AndreaColombo, RenzoColecchia, MaurizioLuciano, RobertaMoschini, MarcoRoss, Jeffrey S.Briganti, AlbertoMontorsi, FrancescoDe Cobelli, FrancescoNecchi, Andrea
- [42] Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy prior to radical cystectomy (RC) in patients with muscle-invasive bladder cancer (MIBC).JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)Rose, Tracy L.Harrison, Michael RogerDeal, Allison MaryOsterman, Chelsea K.Ramalingam, SundharWhang, Young E.Brower, Blaine Y.Bjurlin, MarcSmith, Angela B.Nielsen, Matthew E.Tan, Hung-JuiWallen, Eric M.George, Daniel J.Zhang, TianDrier, AnthonyKim, William Y.Milowsky, Matthew, I
- [43] EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)ANNALS OF ONCOLOGY, 2023, 34 : S1340 - S1340Powles, T. B.Valderrama, B. PerezGupta, S.Bedke, J.Kikuchi, E.Hoffman-Censits, J.Iyer, G.Vulsteke, C.Park, S. H.Shin, S. J.Gauna, D. E. CastellanoFornarini, G.Li, J-R.Gumus, M.Mar, N.Narayanan, S.Yu, X.Gorla, S.van der Heijden, B. M. S. Homet Moreno
- [44] EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)ANNALS OF ONCOLOGY, 2023, 34 : S1557 - S1558Powles, T. B.Perez Valderrama, B.Gupta, S.Bedke, J.Kikuchi, E.Hoffman-Censits, J.Iyer, G.Vulsteke, C.Park, S. H.Shin, S. J.Castellano Gauna, D. E.Fornarini, G.Li, J-R.Gumus, M.Mar, N.Narayanan, S.Yu, X.Gorla, S.Moreno, B. Hometvan der Heijden, M. S.
- [45] Utility of pre- and post-pembrolizumab (Pembro) Vesical Imaging-Reporting and Data System (VI-RADS) to predict the pathological response in muscle-invasive urothelial bladder cancer (MIBC): An analysis of the PURE-01 cohortEUROPEAN UROLOGY, 2023, 83 : S771 - S771Necchi, A.Basile, G.Bandini, M.Raggi, D.Marandino, L.Costa, De Padua T.Patane, D.Crupi, E.Del Prete, A.Colombo, R.Colecchia, M.Luciano, R.Moschini, M.Ross, J.Gibb, E.Briganti, A.Montorsi, F.De Cobelli, F.Brembilla, G.
- [46] Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC)-2-year event-free survival and safety data for Cohort HJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)O'Donnell, Peter H.Hoimes, Christopher J.Rosenberg, Jonathan E.Petrylak, Daniel P.Mar, NataliyaBarata, Pedro C.Srinivas, SandyGourdin, Theodore StewartHenry, ElizabethBilen, Mehmet AsimGeorge, SabyRao, SantoshAssikis, Vasileios J.Burgess, Earle F.Lewis, Brian E.Bowman, I. AlexBrancato, Sam JosephMildiner-Earley, ShirlyZhu, YalinFlaig, Thomas W.
- [47] Interim results from PURE-01: A phase 2, open-label study of neoadjuvant pembrolizumab (pembro) before radical cystectomy for muscle-invasive urothelial bladder carcinoma (MIUC).JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)Necchi, AndreaBriganti, AlbertoRaggi, DanieleGiannatempo, PatriziaMariani, LuigiMessina, AntonellaAnichini, AndreaCalareso, GiuseppinaCrippa, FlavioCatanzaro, MarioFossati, NicolaGandaglia, GiorgioSalonia, AndreaSalvioni, RobertoMontorsi, Francesco
- [48] INTERIM RESULTS FROM PURE-01: A PHASE 2, OPEN-LABEL STUDY OF NEOADJUVANT PEMBROLIZUMAB (PEMBRO) BEFORE RADICAL CYSTECTOMY FOR MUSCLE-INVASIVE UROTHELIAL BLADDER CARCINOMA (MIUC)JOURNAL OF UROLOGY, 2018, 199 (04): : E238 - E238Necchi, AndreaBriganti, AlbertoRaggi, DanieleGiannatempo, PatriziaBianchi, MarcoMariani, LuigiMessina, AntonellaAnichini, AndreaFreschi, MassimoColecchia, MaurizioSalvioni, RobertoColombo, RenzoGallina, AndreaMontorsi, Francesco
- [49] Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)Balar, Arjun VasantKulkarni, Girish S.Uchio, Edward M.Boormans, JoostMourey, LoicKrieger, Laurence Eliot MilesSinger, Eric A.Bajorin, Dean F.Kamat, Ashish M.Grivas, PetrosSeo, Ho KyungNishiyama, HiroyukiKonety, Badrinath R.Nam, KijoengKapadia, EktaFrenkl, Tara L.De Wit, Ronald
- [50] Preoperative pembrolizumab (pembro) before radical cystectomy (RC) for muscle-invasive urothelial bladder carcinoma (MIUC): Interim clinical and biomarker findings from the phase II PURE-01 studyCANCER RESEARCH, 2018, 78 (13)Necchi, AndreaBriganti, AlbertoBianchi, MarcoRaggi, DanieleGiannatempo, PatriziaFreschi, MassimoColecchia, MaurizioFossati, NicolaGandaglia, GiorgioColombo, RenzoGallina, AndreaSalonia, AndreaSalvioni, RobertoAli, Siraj M.Chung, Jon H.Montorsi, Francesco